Cardiovascular effects of raloxifene hydrochloride

Cardiovascular Drug Reviews

Volumn 19, Issue 1, 2001, Pages 57-74

  Saitta, Antonino ^a   Morabito, Nunziate ^a   Frisina, Nicola ^a   Cucinotte, Domenico ^b   Corrado, Francesco ^a   D'Anna, Rosario ^a   Altavilla, Domenica ^a   Squadrito, Giovanni ^a   Minutoli, Letteria ^a   Arcoraci, Vincenzo ^a   Cancellieri, Francesco ^a   Squadrito, Francesco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE

Author keywords

Cardiac protection; Estrogen agonists; Estrogens; Homocysteine; Nitric oxide; Osteoporosis; Raloxifene; SERMs; Vasodilation

Indexed keywords

DROLOXIFENE; ENDOTHELIN 1; ESTROGEN; HOMOCYSTEINE; IDOXIFENE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; RALOXIFENE; TAMOXIFEN; TRIACYLGLYCEROL;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BREAST CANCER; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DOSE RESPONSE; DRUG ABSORPTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENDOTHELIUM; HEART PROTECTION; HOT FLUSH; HUMAN; LIGAND BINDING; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035069715     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2001.tb00183.x     Document Type: Review

References (100)

1. Effect of conjugated estrogen on peripheral flow mediated vasodilation in postmenopausal women
2. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid
3. Differential expression of estrogen receptors a and b mRNA during differentiation of human osteoblast SV-HFO cells
4. Clinical uses of antiestrogens
5. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles
6. Estrogen and coronary heart disease in women
7. Hormonal treatment of postmenopausal women
8. Antagonism of estrogen action with a new benzothiophene derived antiestrogen
9. Raloxifene (LY 139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
10. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits
11. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women
12. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide
13. Molecular basis of agonism and antagonism in estrogen receptor
14. Endothelial dysfunction in atherosclerosis
15. Phase II evaluation of LY 156758 in metastatic breast cancer
16. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits
17. Endothelial dysfunction: Does it matter? Is it reversible?
18. Estrogen receptor ligands modulate its interaction with DNA
19. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys
20. The use of estrogen and progestins and the risk of breast cancer in postmenopausal women
21. Alternative mechanism of action of anti-oestrogens
22. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial
23. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
24. Effects of raloxifene in postmenopausal women
25. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women; a 2-year, placebo-controlled study
26. Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity
27. Expression of estrogen receptor-beta in human breast tumors
28. Antiestrogenic properties of raloxifene
29. A controlled trial of raloxifene (LY 138481) HCI: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
30. Vasodilator-derived nitric oxide inhibits fetal calf serum and angiotensin-II-induced growth of renal arteriolar smooth muscle cells
31. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-α1 promoter via a novel sequence
32. The vascular protective effects of estrogens
33. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism
34. In vivo and in vitro metabolism of raloxifene
35. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor
36. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators
37. Activation of the ovolabumin gene by the estrogen receptor involves the fos-jun complex
38. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women
39. Acute vascular effects of estrogen in postmenopausal women
40. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
41. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in atymic mice
42. Structure-activity relationship of selective estrogen receptor modulators: Modifications to the 2-arylbenzothiophene core of raloxifene
43. Molecular determinants of tissue selectivity in estrogen receptor modulators
44. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
45. Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription
46. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury
47. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
48. Alternate antiestrogens and approaches to the prevention of breast cancer
49. Incident primary breast cancers are reduced by raloxifene: Integrated data from multicenter, double-blind, randomized trials in ∼ 12,000 postmenopausal women
50. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis of the cell- and promoter-specific action of these hormones
51. Keoxifene (LY 156758) inhibits follicle-stimulating hormone induced differentiation of cultured rat granulose cells
52. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women
53. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
54. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
55. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans
56. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture
57. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms
58. Estrogen improves endothelial-dependent flow-mediated vasodilation in post-menopausal women
59. Disposition and metabolism of new benzothiophene antiestrogen in rats dogs and monkeys
60. Nitric oxide and its role in the cardiovascular system
61. The role of endothelin in coronary atherosclerosis
62. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
63. Endothelial dysfunction in coronary heart disease
64. Paradoxical influence of estrogenic hormones on platelet endothelial cells interactions
65. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women
66. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: A randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens
67. Randomized, double-blind, placebo controlled study on the effects of raloxifene and hormone replacement therapy on plasma nitric oxide concentrations, endothelin-1 levels and endothelium-dependent vasodilatation in postmenopausal women
68. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model
69. Erb: Identification and characterization of a novel human estrogen receptor
70. Effect of 17-β estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis
71. Inhibitory actions of keoxifene on luteinizing hormone secretion in pituitary gonadotrophs
72. Differential ligand activation of estrogen receptor ERα and ERβ at AP1 sites
73. Suppression of spontaneous LH surges in estrogen-treated ovariectomized rats by microimplants of antiestrogens into the preoptic brain
74. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women
75. Tibolone as an alternative to estrogen for the prevention of postmenopausal osteoporosis in selected postmenopausal women
76. Circulating nitric oxide(nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate. A two-year follow-up study
77. Advantages of raloxifene over alendornate or estrogen on nonreproductive tissues in the long-term dosing of ovariectomized rats
78. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial
79. Comparative distribution of estrogen receptor α and β mRNA in the rat central nervous system
80. Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs
81. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo
82. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function
83. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
84. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study
85. Antioxidant potential of specific estrogens on lipid peroxidation
86. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
87. Raloxifene preserves bone strength and bone mass in ovariectomized rats
88. Regulatory functions of the vascular endothelium
89. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer
90. Non-steroidal antiestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells
91. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
92. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
93. Tamoxifene activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
94. Non-genomic effects of estrogens and antiestrogens
95. Estrogen modulates responses of atherosclerotic coronary arteries
96. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys
97. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene
98. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1
99. Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study